Full-Time
Clinical Business Manager
Magnetic Resonance Imaging
Philips
Healthcare technology for diagnosis, care, wellness
Compensation Overview
CA$154.5k - CA$179k/yr
Montreal, QC, Canada + 3 more
More locations: Toronto, ON, Canada | Ottawa, ON, Canada | Québec City, QC, Canada
In Person
Must reside in eastern Canada; relocation benefits are not provided. Field role requires travel, including overnight stays.
Bachelor's
 Sales & Account Management (1) |
|---|
- You have acquired 5+ years of direct clinical magnetic resonance imaging experience.
- You have a Bachelor's degree or equivalent education, experience, or certifications, including accredited magnetic resonance imaging or medical radiation technologist education and Canadian Association of Medical Radiation Technologists certification.
- You have deep product knowledge and expertise within the magnetic resonance imaging modality and a strong understanding of the Canadian healthcare system, particularly in diagnostic imaging.
- Bilingual French and English skills, both written and verbal, are required.
- You can effectively manage and influence internal and external stakeholders.
- You must be willing to travel, including overnight stays.
- Canadian work authorization is a precondition of employment, and candidates requiring sponsorship for a work-authorized visa now or in the future will not be considered.
- You must reside in eastern Canada.
- Establish and maintain strong relationships with key decision-makers by leveraging deep technical and clinical knowledge to build credibility and trust.
- Lead and own the business with a proactive and customer-centric approach to drive customer success, financial growth, and long-term relationships.
- Support the Account Manager and Account Executive in the sales process, from solution definition and design to proposing tailored solutions that address specific customer needs while identifying new opportunities within the assigned territory.
- Provide Marketing with insights into sales tools, pricing issues, and competitive threats so it can support the sales team with current and relevant resources.
- Serve as the subject matter expert on the magnetic resonance imaging portfolio by leveraging technical knowledge to support the Account Manager and Account Executive in addressing customer needs and challenges.
- Hands-on experience with sales or clinical applications in the health technology industry.
Philips develops health technology across professional medical devices, connected care, and consumer health products. Its offerings include diagnostic imaging and image-guided therapy, patient monitoring and clinical informatics, and everyday wellness products like oral and personal care. The company increasingly delivers integrated solutions through a Healthcare-as-a-Service subscription model and long-term partnerships with hospitals and health systems. Its aim is to improve people’s health and well-being by making advanced health technology easier to access and integrate into care.
Company Size
N/A
Company Stage
IPO
Headquarters
Andover, Minnesota
Founded
1891
Simplify's Take
What believers are saying
- May 18, 2026 Stockholm selected Philips for hospital-at-home coverage across up to 15,000 patients annually.
- Q1 2026 sales grew 4%, and Philips reiterated 2026 guidance on May 13, 2026.
- 2025 free cash flow reached EUR 512 million, supporting investment and shareholder returns.
What critics are saying
- August 2026 MDL still holds 624 Philips CPAP cases, extending legal drag.
- January 19, 2026 settlement covers economics only; DOJ consent-decree talks still threaten Respironics.
- A Respironics compliance failure can block U.S. sleep-device sales and tarnish Philips brand.
What makes Philips unique
- June 4, 2026 WellSpan alliance makes Philips preferred vendor across CT, MR, X-ray, ultrasound, image-guided therapy.
- August 6, 2026 ecosystem partnerships connect Philips monitoring from hospital beds to homes.
- Philips combines diagnosis, connected care, and personal health across 64,317 employees at Q1 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.